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Summary
Excess body weight and adiposity cause insulin resistance,
inflammation, and numerous other alterations in metabolic and
hormonal factors that promote atherosclerosis, tumorigenesis,
neurodegeneration, and aging. Studies in both animals and
humans have demonstrated a beneficial role of dietary restriction
and leanness in promoting health and longevity. Epidemiological
studies have found strong direct associations between increasing
body mass index (BMI) and risks of developing type 2 diabetes,
cardiovascular disease, and several types of cancer, beginning
from BMI of 20–21 kg m2. Although a recent meta-analysis
suggests that overweight individuals have significantly lower
overall mortality than normal-weight individuals, these data are
likely to be an artifact produced by serious methodological
problems, especially confounding by smoking, reverse causation
due to existing chronic disease, and nonspecific loss of lean mass
and function in the frail elderly. From a clinical and public health
point of view, maintaining a healthy weight through diet and
physical activity should remain the cornerstone in the prevention
of chronic diseases and the promotion of healthy aging.
Key words: body mass index; calorie intake; disease preven-
tion; health; obesity.
Introduction
Worldwide, an estimated 2.16 billion adults and 170 million children are
overweight [body mass index (BMI) > 25 kg m²] or obese (BMI > 30 kg
m²) (Lobstein et al., 2004; Finucane et al., 2011). In the United States,
an alarming 67% and 33% of the adults are overweight and obese,
respectively (Flegal et al., 2012). Data from animal and human studies
clearly indicate that excess adiposity, especially if centrally located, is
associated with a range of detrimental metabolic alterations that
increase the risk of developing type 2 diabetes, coronary artery disease,
hypertension, stroke, nonalcoholic liver disease, cancer, neurodegener-
ation, and accelerated aging (Tchernof & Despres, 2013). Starting from a
BMI of 20–21 kg m2, rising BMI levels are associated with progressively
increased risks of developing diabetes, cardiovascular disease (CVD), and
several types of cancer, which combined are responsible for approxi-
mately two-thirds of deaths in Western countries (Clinical, 1998).
According to the World Health Organization and many medical
societies, BMI should be maintained in the 18.5–24.9 kg m2 range to
achieve optimum health. However, a recent meta-analysis has suggested
that being overweight, and possibly even mildly obese, is associated with
a reduced mortality risk (Flegal et al., 2013). These findings clearly
contradict evidence from basic scientific, clinical, and epidemiological
studies on the metabolic benefits of maintaining a healthy weight. They
also are inconsistent with data from dietary restriction (DR) studies in
rodents and primates as well as basic research studies on the metabolic
and molecular mechanisms promoting health and longevity. In this
paper, we review and address the effects of overweight and obesity on
health and longevity by integrating evidence from basic, clinical, and
population-based studies. We will also discuss the clinical and public
health implications of these data.
Body mass index and mortality
The relationship between body weight and mortality has been the
subject of debate for several decades. In particular, considerable
controversy has surrounded the shape of the curve for the association
between BMI and mortality, and the effects of overweight on mortality.
In a recent meta-analysis of 97 prospective cohort studies (2.9 million
individuals and 270 000 deaths), Flegal et al. found that compared with
the normal-weight group (18.5–<25 kg m2), the relative risks (RRs) of
death were 0.94 (95% CI, 0.91–0.96) for overweight (25–<30), 0.95
(95% CI, 0.88–1.01) for class 1 obesity (30–<35), and 1.29 (95% CI,
1.18–1.41) for class 2 and 3 obesity (≥35) (Flegal et al., 2013). However,
the validity of these findings has been challenged due to several major
methodological problems (Tobias & Hu, 2013). First, many high-quality
prospective studies and consortia (including >6 million participants) were
excluded from the meta-analyses because they did not use standard BMI
categories (i.e., 18.5–24.9 for normal weight, 25–29.9 for overweight,
and ≥30 for obesity). These large studies generally benefited from
sufficient statistical power to allow for the analysis of finer BMI
categories, and therefore had no reason to use such broad categories.
In most of these omitted studies, the BMI range associated with the
lowest mortality was around 22.5–25, particularly after accounting for
smoking status and reverse causation due to prevalent diseases (Tobias &
Hu, 2013). Second, the meta-analysis included numerous studies
conducted among elderly or sick populations as well as current and
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past smokers. In particular, the broad reference group (BMI 18.5–24.9)
contains not only individuals who are lean and active, but also heavy
smokers, the frail and elderly, and those who are ill with previous weight
loss or diminished weight gain due to existing diseases. Because the
overweight and obese groups were compared with this heterogeneous
group, the associations with the higher-BMI groups were seriously
underestimated, creating an artifact of reduced mortality among the
overweight and moderately obese groups (Willett et al., 2013).
Reverse causation (i.e., low BMI being the result of underlying illness
rather than the cause) is the most serious concern in analyzing the
relationship between BMI and mortality (Hu, 2008). Weight loss can
result from the direct effects of chronic disease on weight or from
conscious efforts motivated by a diagnosis of serious illness. Many
conditions that cause weight loss, such as chronic obstructive pulmonary
disease, depression, and neurodegenerative diseases, may remain
undiagnosed for years. For example, weight loss in patients with
Parkinson’s disease starts 7–8 years before diagnosis (Chen et al., 2003).
To minimize the impact of reverse causation, it is important to exclude
patients with existing chronic diseases at baseline (Hu, 2008). Also,
residual confounding by preclinical or undiagnosed conditions may
attenuate the effects of obesity on mortality. Excluding deaths during
the first few years of follow-up can also reduce bias due to reverse
causation, because those with existing or occult diseases tend to die
early in follow-up (Hu, 2008).
The problem of reverse causation becomes even more pronounced in
studies among older individuals as the prevalence of chronic diseases
increases with age. Thus, age has been found to be an apparent effect
modifier in the association between BMI and mortality, suggesting
attenuation in the positive association between BMI and mortality
among older age groups. In addition to greater bias due to higher
prevalence of chronic diseases in the elderly, BMI is a less valid measure
of excess body fat in older populations due to differential loss of muscle
mass related to aging (sarcopenia or frailty) (Manson et al., 2007). In the
Cancer Prevention Study II, stratified analyses by three age groups (30–
64 years, 65–74 years, and ≥75 years) showed stronger association of
mortality associated with increasing BMI in younger than older partic-
ipants (Calle et al., 1999). However, because overall mortality is much
higher in the elderly, the absolute increase in death rates associated with
higher BMIs was much greater in people ≥75 years old than in middle-
aged individuals (Fig. 1) (Byers, 2006). Thus, the reduced relative impact
of obesity on mortality does not mean that obesity is not detrimental in
the elderly.
The ‘obesity paradox,’ i.e., the association of obesity with improved
survival or decreased mortality, is commonly observed among patients
with wasting conditions (e.g., congestive heart failure, end-stage renal
disease, advanced malignancies, and AIDS). In these populations,
increased blood pressure and serum cholesterol concentrations are also
associated with improved survival (Curtis et al., 2005). A biological basis
for the obesity paradox is unclear; it has been suggested that higher BMI
among the chronically ill may confer survival benefits by providing
‘metabolic or nutritional reserve,’ but this hypothesis has yet to be
tested. On the other hand, methodological bias from reverse causation is
a more plausible explanation, because patients with low BMI, blood
pressure, and cholesterol usually have more severe disease and are
associated with greater frailty and a more rapid decline in physical health
(Hu, 2008). Thus, the mortality risk in the low-BMI group is substantially
increased, resulting in artificially low mortality rates in the higher-BMI
groups. Another explanation for the obesity paradox is survival bias or
depletion of susceptibles, due to more frequent premature deaths
among those most vulnerable to obesity-related complications. This bias
is exacerbated in short-term follow-up studies.
Confounding by smoking is also a major concern, because smokers
tend to weigh less than nonsmokers but have substantially higher
mortality rates (Manson et al., 1987). Although adjustment for smoking
can reduce the impact of confounding, statistical adjustment for
smoking status is typically inadequate due to complex variations in
duration of smoking and degrees of inhalation. The best way to
minimize residual confounding by smoking is to restrict analyses to
never-smokers. Because reverse causation and confounding by smoking
typically coexist in a population, it is important to simultaneously exclude
both persons with known chronic disease and smokers from the analyses
to obtain valid estimates.
To account for smoking and reverse causation due to prevalent
diseases, two large pooled analyses of individual-level data from more
than two million people have been recently published. In the Prospective
Studies Collaboration, the analyses were adjusted for age, sex, and
smoking status (Whitlock et al., 2009). The first five years of follow-up
were excluded to limit reverse causation. Mortality was lowest at a BMI
of 22.5–25 for both sexes. Above this range, each five-unit increment in
BMI was associated with about 29% higher overall mortality ([95% CI
27–32%]); below this range, excess mortality was due mainly to
smoking-related diseases. Stratified analysis by smoking status revealed a
relatively direct linear relationship among nonsmokers, while a nonlinear
J-shaped relationship persisted among smokers.
In the National Cancer Institute Cohort Consortium, which included
19 cohorts and 1.46 million people, the age-standardized rate of death
from any cause was lowest among participants with a BMI of 22.5–24
(Berrington de Gonzalez et al., 2010). Among female healthy partici-


















































































Fig. 1 Risk of death associated with body mass index among male nonsmokers
without chronic health conditions, according to age. The annual risk of death is
expressed as both the RR (Panel A) and the absolute amount of additional risk (risk
difference) (Panel B) per 100 000 population, as reported in the American Cancer
Society Cancer Prevention Study 2. From: Byers T (2006). Overweight and mortality
among baby boomers–now we’re getting personal. N Engl J Med 355,758–60.
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category, RRs of mortality were 1.13 for a BMI of 25.0–29.9; 1.44 for a
BMI of 30.0–34.9; 1.88 for a BMI of 35.0–39.9; and 2.51 for a BMI of
40.0–49.9. The results were similar for men. When BMI was analyzed as
a continuous variable, the RR for each five-unit increase was 1.31 (95%
CI, 1.29–1.33) over the range of 25.0–49.9. The association between
BMI and mortality increased with longer duration of follow-up. When
stratified by age of BMI ascertainment, the RRs were stronger in the
younger age groups (<70 years old) than the older age group
(≥70 years).
Taken together, these two large pooled analyses of individual-level
data, along with data from several large well-established individual
cohort studies, convincingly show that BMI values associated with the
lowest mortality were generally below 25, and that being overweight or
moderately obese was associated with significantly increased risk of
mortality, especially among healthy nonsmokers. Of note, pooled
analyses of individual-level data are usually superior to meta-analyses
of published estimates, because the former can standardize exposure
and covariate definitions, exclusion criteria, and methods for statistical
adjustments, and easily facilitate crucial stratified analyses.
Fat distribution and mortality
Abdominal or central obesity, reflected by a higher waist circumference
and waist-to-hip ratio (WHR), has been associated with increased
mortality, independent of BMI (Zhang et al., 2008). In the NHS cohort,
after adjustment for BMI and potential confounders, the RRs across the
lowest to the highest waist circumference quintiles were 1.00, 1.11,
1.17, 1.31, and 1.79 (95% CI, 1.47–1.98) for all-cause mortality. Among
normal-weight women, abdominal obesity was significantly associated
with increased CVD mortality: RR associated with waist circumference ≥
88 cm was 3.02 (95% CI, 1.31–6.99) and for WHR ≥ 0.88 was 3.45
(95% CI, 2.02–6.92). The strong association between WHR and
mortality in normal-weight women suggests that a relatively high
degree of abdominal adiposity is deleterious despite being normal
weight. These results clearly demonstrate the importance of abdominal
obesity in predicting mortality. However, the studies do not diminish the
importance of overall adiposity, particularly in younger and middle-aged
people due to a strong correlation between BMI and waist circumference
(r > 0.80) (Hu, 2008).
BMI and morbidity
Epidemiological studies provide overwhelming evidence that above a
BMI of 20–21, a strong and linear association exists between BMI and
the risk of developing type 2 diabetes, hypertension, CVD, cholelitiasis,
and other chronic diseases in both men and women (Fig. 2A,B) (Willett
et al., 1999). The strongest magnitude of association is observed for
diabetes. There also appears to be a linear relationship between BMI and
coronary heart disease (CHD), which is particularly evident among Asian
populations. Jee and colleagues published a detailed analysis of BMI and
CHD incidence among 133 740 Korean participants during nine years of
follow-up (Jee et al., 2005). After adjustment for age, sex, and smoking
status, each 1-unit increase in BMI was associated with a 14% (95% CI,
12–16%) increased risk of incident CHD. Compared with a BMI of 18–
18.9, even a normal BMI of 24–24.9 was associated with a twofold
increased risk of CHD.
Significant weight gain from young adulthood through midlife is
common and largely reflects increases in body fat. Large cohort studies
have found a strong dose–response relationship between the amount of
weight gained since young adulthood (age 18 for women and age 20 for
men) and risk of developing diabetes, hypertension, CHD, and chole-
lithiasis (Fig. 2C,D). Even a modest amount of weight gain (<5 kg) since
(A) (C)
(B) (D)
Fig. 2 Relation between body mass index
up to 30 and the relative risk of type 2
diabetes, hypertension, coronary heart
disease, and cholelithiasis in women (Panel
A) and men (Panel B). Relation between the
change in weight and the relative risk of
type 2 diabetes, hypertension, coronary
heart disease, and cholelithiasis in women
(Panel C) and men (Panel D). From: Willett
WC, Dietz WH, Colditz GA (1999).
Guidelines for healthy weight. N Engl J
Med. 341, 427–434.
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young adulthood was significantly associated with an increased risk of
several chronic diseases independent of baseline weight. Greater weight
gain (e.g., 11–19 kg) was associated with twofold increased risk of CHD
in a cohort of women (Willett et al., 1995). Therefore, monitoring
weight change since young adulthood can provide a sensitive and useful
clinical measure for early detection of adverse trends in chronic disease
risk.
Convincing evidence from epidemiological studies indicates that
excess adiposity contributes to the increased incidence and/or death
from cancers of the colon, female breast (in postmenopausal women),
endometrium, kidney (renal cell), esophagus (adenocarcinoma), gastric
cardia, pancreas, gallbladder, and liver (Calle & Kaaks, 2004). Compared
to normal weight, both overweight and obesity are associated with
significantly increased risks of these cancers, attributing to 15–20% of all
cancer deaths in the USA (Calle et al., 2003).
Body fat distribution, measured by waist circumference or WHR, has
also been associated with metabolic disease, CVD, and several major
cancers independent of BMI and other risk factors (Hu, 2008). However,
including BMI and waist circumference in a model simultaneously tends
to attenuate the effects of BMI. It should be noted that, after adjusting
for waist circumference, the interpretation of BMI is altered, such that
BMI now largely reflects the effects of lean body mass rather than overall
adiposity. Nonetheless, measuring waist circumference among normal-
weight individuals can provide additional predictive power of disease risk
beyond BMI.
Increasing physical fitness or becoming physically active can reduce
the adverse impacts of overweight and obesity on health (LaMonte &
Blair, 2006). However, physical activity does not completely eliminate the
adverse effects of obesity on disease risk. Similarly, being lean does not
entirely counteract the increased risk associated with physical inactivity.
Individuals who are both lean and physically active tend to have the
lowest risk of chronic disease incidence and mortality (Hu et al., 2004).
These findings indicate that leanness, accompanied or achieved by an
active lifestyle, is the optimal way to reduce the risk of chronic diseases,
and that excess adiposity remains a concern even among active
individuals.
Optimal weight and successful aging
The concept of successful aging includes not only the absence of major
chronic diseases but also the maintenance of sound cognitive, physical,
and other functions (Rowe & Kahn, 1997). Traditional cardiovascular risk
factors such as smoking and physical inactivity have been associated with
a decreased probability of successful aging. However, few studies have
examined whether adiposity affects healthful aging among those who
survive to older ages. Given that more people survive to older ages, it is
critical to identify the optimal body weight to predict healthy aging. In
the Hawaii Lifespan Study, a study of aging men from the Honolulu
Heart Program/Honolulu-Asia Aging cohort, being overweight in midlife
was associated with a significantly reduced probability of healthy survival
to age 85 or older among men (Willcox et al., 2006). Whether this
finding can be generalized to women or other ethnic groups remains
unclear.
Adiposity in early adulthood and midlife has been associated with
decreased probability of healthy survival at age 70 or older in the Nurses’
Health Study (NHS) (Sun et al., 2009). Healthy survivors were partici-
pants who survived to age 70 free from major chronic diseases (cancer,
diabetes, CVD, kidney failure, chronic obstructive pulmonary disease,
and neurodegenerative disease), had no major impairment of cognitive
function, had no major limitation of physical functions, and were in good
mental health. In the NHS cohort, approximately 10% of participants
were designated ‘healthy survivors.’ After adjustment for multiple
potential confounding factors, every one-unit increase in BMI was
associated with a 12% reduction in the odds of healthy survival (95% CI
10–14%). Compared with lean women (BMI 18.5–22.9), obese women
(BMI ≥ 30) had 79% lower odds of healthy survival to the age of ≥70
(95% CI 71–85%). In addition, weight gain since age 18 was associated
with decreased odds of healthy survival after the age of 70 in a dose–
response manner (Fig. 3). Even a moderate weight gain of 4–10 kg was
significantly associated with reduced odds of healthy survival.
Collectively, this evidence underscores the importance of maintaining
a healthy weight throughout adulthood to enjoy a long and healthy life.
All three metrics in the ‘adiposity triad’ (Hu, 2008) (BMI, waist
circumference, and weight gain since young adulthood) are important
in assessing the relationship between adiposity and healthy aging,
because each adds information to the risk prediction and offers a unique
aspect of potential goals and targets for prevention.
Linking metabolic pathways to chronic diseases: Fat tissue as
an endocrine organ
Accumulating evidence indicates that adipose tissue is not just an inert
store of excessive energy intake, but is also an active endocrine organ
that produces key hormones, called adipokines, that regulate several
important biological functions (Fig. 4) (Kershaw & Flier, 2004). Excessive
energy intake, particularly in sedentary people, leads to a chronic positive
energy balance, resulting in weight gain, increased visceral adiposity,
dysfunctional enlarged adipocytes with macrophages infiltration, lipid
overflow, and deposition of ectopic fat in key organs, such as liver, heart,
skeletal muscle, kidney, and pancreas (Tchernof & Despres, 2013). Both
hypertrophic fat cells and infiltrated inflammatory cells secrete
inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis
factor (TNF)-a, causing a local and systemic low-grade inflammation. This























Gain ≥ 10 kg
18.5-22.9 ≥ 25
Body mass index at age 18 years (kg/m2)
23-24.9
Fig. 3 Joint effect of body mass index at age 18 and weight change on healthy
survival in the Nurses’ Health Study. Adjusted odds with 95% confidence intervals.
Multivariable model adjusted for age (years), education (registered nurse, bachelor,
master, or doctoral degree), husband’s education (less than high school, some high
school, high school graduate, college graduate, or graduate school), marital status
(married, widowed, separated/divorced/never married), postmenopausal hormone
use (never used, past user, or current user), smoking status (never smoked, past
smoker, current smoker 1–14, 15–24, or ≥25 cigarettes/day), family history of
heart disease (yes/no), family history of diabetes (yes/no), family history of cancer
(yes/no), vigorous physical activity (hour/week), polyunsaturated–saturated fat
ratio (in fifths), intakes of trans fat, alcohol, and cereal fiber (all in fifths), and
intakes of fruits and vegetables and red meat (in thirds), all defined at baseline.
From Sun Q, Townsend MK, Okereke OI, Franco OH, Hu FB, Grodstein F (2009).
Adiposity and weight change in midlife in relation to healthy survival after age 70
in women: prospective cohort study. BMJ. 339, b3796.
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of atherosclerosis, cancer, dementia, and aging (Fontana et al., 2007a;
Gregor & Hotamisligil, 2011). Inflammation and reduced production of
adiponectin (an adipocyte-derived adipokine) from enlarged visceral fat
cells in overweight and obese individuals are associated with insulin
resistance, increased hepatic glucose production, and altered lipopro-
tein–lipid metabolism (i.e., hypertriglyceridemia, low HDL cholesterol,
and small, dense LDL particles), contributing to the development of type
2 diabetes, nonalcoholic fatty liver disease, and CVD (Tchernof &
Despres, 2013; National Institutes of Health, 1998; Gregor & Hotami-
sligil, 2011; Turer & Scherer, 2012). Moreover, adipokine-mediated
insulin resistance triggers compensatory hyperinsulinemia, which exerts
powerful mitogenic procancer effects directly, and also indirectly by
increasing the bioavailability of sex hormones and insulin-like growth
factor (IGF)-1, and the ovarian production of androgens. Enlarged
adipocytes also secrete molecules such as leptin, IGF-1, IL-6, and type VI
collagen that promote cell survival and tumor growth (Calle & Kaaks,
2004; Roberts et al., 2010). Insulin resistance, hyperinsulinemia, and
adipokine imbalance, in conjunction with overactivation of the renin-
angiotensin-aldosterone and the sympathetic nervous systems, have also
been implicated in the pathogenesis of hypertension in overweight and
obese individuals (Tchernof & Despres, 2013).
A 5–10% weight loss induced by a negative energy balance (i.e.,
calorie restriction, endurance exercise, bariatric surgery) simultaneously
improves multiple metabolic and hormonal factors implicated in the
pathogenesis of several lethal chronic diseases, as well as in the biology
of aging itself (Goldstein, 1992). Weight loss induced by a negative
energy balance is associated with a reduction in visceral, hepatic, and
skeletal muscle fat, decreased fat cell size, increased adiponectin and
insulin sensitivity, and reduced circulating levels of insulin and leptin
(Larson-Meyer et al., 2006; Uusitupa et al., 2003; Turer & Scherer,
2012). Weight loss is also associated with improved blood pressure,
serum triglycerides, and HDL-cholesterol concentrations. (Dattilo &
Kris-Etherton, 1992; Stevens et al., 2001). Decreases in adiposity also
leads to reductions in inflammatory cytokines and prostaglandins,
oxidative stress and DNA damage, and circulating estrogens due to
inhibition of aromatases (Davı et al., 2002; Ziccardi et al., 2002; Hofer
et al., 2008). Other hormonal adaptations associated with fat loss,
improved insulin sensitivity, and reduced cancer risk include increased
serum steroid hormone binding globulin and reduced levels of free
estrogens and testosterone, and increased serum IGFBP-1 and reduced
free IGF-1 concentrations (Longo & Fontana, 2010; Demark-Wahnefried
et al., 2012).
The beneficial effects of sustained weight loss induced by a negative
energy balance have recently been confirmed in nonrandomized,
prospective, controlled studies, in which morbidity and mortality from
diabetes, CVD, and cancer were dramatically reduced among obese
gastric bypass surgery patients (Sj€ostr€om et al., 2007; Carlsson et al.,
2012). Nonetheless, experimental studies indicate that a reduction in fat
mass alone (i.e., surgical removal of large quantities of subcutaneous
abdominal fat or omental fat) without modifications in energy balance
does not improve insulin sensitivity, inflammation, or other cardiomet-
abolic risk factors in obese patients (Klein et al., 2004; Fabbrini et al.,
2010), indicating that induction of a negative energy balance is required
to achieve the metabolic benefits of weight loss.
Health benefits of achieving a healthy weight through
dietary restriction
It is well established that diet and exercise-induced weight loss improve
metabolic and cardiovascular health. Data from experimental studies
show that dietary restriction (DR), defined as a reduction in food intake
below usual ad libitum intake without malnutrition, and avoiding the
excessive energy intake that leads to overweight and obesity, is the most
powerful intervention to extend healthy lifespan in mammals (Weind-
ruch & Walford, 1988; Masoro, 2005; Fontana & Klein, 2007). However,
the ideal body weight, percent adiposity, and metabolic profile associ-
ated with healthy longevity and the lowest risk of developing chronic
disease remain unknown. Data from hundreds of studies conducted in
simple model organisms and small mammals clearly indicate that
restricting caloric intake by 30–50% slows aging and markedly extends
average and maximal lifespan (Weindruch & Walford, 1988; Masoro,
2005; Fontana et al., 2010). Not only do ‘super-lean’ DR mice and rats
live up to 50% longer, but also they are protected against cancer,
cardiomyopathy, nephropathy, diabetes, neurodegenerative disease,
and chronic lung and autoimmune diseases (Weindruch & Walford,
1988; Masoro, 2005; Fontana & Klein, 2007). Rather than simply
prolonging the survival of an old, frail, and ill animal, DR maintains the
physiological functions of these mammals in more youthful states
compared with age-matched control animals with free access to food.
For example, sarcopenia, left ventricular diastolic dysfunction, decline in
heart rate variability, presbycusis, and neurodegeneration are prevented
or delayed in DR rodents (Marzetti et al., 2009; Meyer et al., 2006;
Mager et al., 2006; Someya et al., 2010; Martin et al., 2006). Addi-
tionally, data from postmortem pathological studies have shown that
30% of the DR rodents vs. 6% of fatter ad-libitum-fed animals die in old
age free of pathological lesions (Shimokawa et al., 1993). Data from two
ongoing primate studies show that 30% DR, started at a young age and
sustained for 20 years, is safe and results in a more than a 50%
reduction in cardiovascular and cancer morbidity and mortality (Colman
et al., 2009; Mattison et al., 2012). In the Wisconsin study, type 2
diabetes and glucose intolerance were completely prevented and age-
dependent decline in skeletal muscle mass, auditory function, and brain
volume were significantly attenuated in DR monkeys compared with the
ad-libitum control group (Colman et al., 2008, 2009; Someya et al.,
2010). In this study, but not in the NIA study, age-related mortality was
PAI-1, Angiotensinogen, IGF-1, TGF-β,
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Fig. 4 Adipose tissue as an endocrine organ. A chronic positive energy balance
induces adipose tissue expansion (red circles) and recruitment of M1 stage
macrophages. Enlarged adipocytes and activated macrophages secrete proteins
and lipids, called adipokines, that promote inflammation (e.g., IL-6, TNF-alpha,
MCP-1, MIF, resistin), insulin resistance (reduced adiponectin and omentin;
increased TNF-alpha, leptin, RBP4, resistin, and nonesterified free fatty acids), cell
proliferation (leptin, IGF-1, TGF-b, adipocyte-derived type VI collagen), and blood
pressure and coagulation dysfunction.
Optimal body weight for healthy longevity, L. Fontana and F. B. Hu 395
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
significantly lower in the DR than in the control monkeys; however, both
studies found that the percentage of animals free of age-related diseases
was higher in the DR than in the control group (Colman et al., 2009;
Mattison et al., 2012).
A series of randomized, controlled intervention trials have recently
tested the effect of DR on metabolic health and age-related markers in
nonobese men and women. The 1-year Washington University CALERIE
(Comprehensive Assessment of Long-term Effects of Reducing Intake of
Energy) trial demonstrated that a 14% DR and a 14% increase in energy
expenditure through endurance exercise reduced visceral fat mass by
~35%and improved lipidprofile, glucose tolerance, and insulin action, and
reduced inflammation (Fontana et al., 2007b; Weiss et al., 2006). Results
from the 6-month Pennington Center CALERIE trial show that a 13% DR
decreased visceral fat mass, metabolic rate, body temperature, insulin
resistance, andoxidative stress (Heilbronnet al., 2006).Observational data
from healthy individuals practicing long-term DR with adequate nutrition
(at least 100% of the RDI for each nutrient) show that even in these lean
participants (mean BMI 19.6 kg m2; ~12% body fat), DR induces
beneficial changes against aging-related pathologies. In these individuals,
DRcaused rapidandprofound improvements in all themajor risk factors for
CVD, including total cholesterol–HDL ratio (2.6  0.5), triglycerides
(48  15 mg dL1), fasting glucose (81  7 mg dL1), systolic
(99  10 mmHg) and diastolic (61  6 mmHg) blood pressure, inflam-
matory markers (C-reactive protein, 0.3  0.2 mg L), and intima-media
thickness (0.5  0.1 mm) of the carotid arteries (Fontana et al., 2004;
Holloszy & Fontana, 2007). This ‘super-physiological’ cardiometabolic
profile in theCRpractitionersmost likelywill result in a very-low lifetime risk
of developing CVD and in a markedly longer median survival as suggested
by longitudinal data of the Framingham Heart Study (Lloyd-Jones et al.,
2006). Not only did DR in these lean individuals result in an optimal
cardiovascular profile, but two markers of cardiovascular aging (i.e., left
ventricular diastolic function and heart rate variability) were also signifi-
cantly improved, consistent with the same adaptations seen in DR rodents
(Meyer et al., 2006; Stein et al., 2012). Moreover, several metabolic and
hormonal factors that havebeenassociatedwith increased cancer risk (i.e.,
abdominal adiposity, insulin, testosterone, estradiol, leptin, and inflam-
matory cytokines) were all significantly lower in the DR group than in the
nonobese controls (Longo & Fontana, 2010). Finally, the beneficial health
effects of chronic DR are further supported by data collected from
inhabitants of Okinawa Prefecture, Japan, who until 1960 had an average
caloric intake 40% lower than US residents, a mean BMI of ~21 kg m2,
80% lower rates of CVD and cancer mortality than the average US
population, andoneof thehighestproportionsof centenarians in theworld
(Willcox et al., 2007).
Metabolic and molecular mechanisms underlying longevity
and healthy aging
The exact molecular mechanisms underlying the beneficial effect of DR
and the detrimental effects of a sustained positive energy balance
leading to excessive adiposity remain unknown. However, data from
dietary, genetic, and pharmacological studies in animal models of
longevity and accelerated aging indicate that metabolism plays a crucial
role in regulating health and survival (Kenyon, 2005; Russell & Kahn,
2007; Buffenstein & Pinto, 2009; Fontana et al., 2010; Selman &
Withers, 2011). As shown in Fig. 5, many DR-induced interrelated and
overlapping metabolic, molecular and cellular adaptations have been
proposed to play a role in extending healthspan and lifespan (reviewed
in-depth by Fontana & Klein, 2007; Chen et al., 2010; Fontana et al.,
2010; Kourtis & Tavernarakis, 2011; Guarente, 2013; Lopez-Otın et al.,
2013). In particular, down-regulation of the key cellular nutrient-sensing
pathways (e.g., the IGF/insulin/Akt/FOXO/mTOR pathway) has been
shown to reduce disease risk and increase healthy survival in experimen-
tal animals (Fontana et al., 2010; Johnson et al., 2013). Consistently,
several functional mutations of the human IGF-IR and FOXO3a gene,
which results in down-regulation of the insulin/IGF signaling pathway,
have been associated with extreme longevity in humans (Bonafe et al.,
2003; Suh et al., 2008; Willcox et al., 2008; Flachsbart et al., 2009).
Excessive intake of energy and essential amino acids stimulates this
pathway, whereas calorie and protein restriction inhibits its activity
(Giovannucci et al., 2003; Fontana et al., 2008, 2010; Efeyan et al.,
2012; Mercken et al., 2013). Other metabolic factors that have been
implicated in the pathogenesis of aging, but also frailty, and involuntary
weight loss in both experimental studies of both animals and humans are
inflammation, increased cortisol, and reduced levels of sex hormones and
triidothyronine (Clegg et al., 2013). Although we do not yet know
whether chronic inflammation is causally linked to the reduction in IGF-1,
testosterone, and triidothyronine in elderly frail individuals, all of these
factors are strong predictors of multidimensional impairment and
mortality. Interestingly, however, lower IGF-1, triidothyronine and
testosterone levels, and increased cortisol concentrations are also typical
adaptations induced by DR in rodents (who live long, healthy lives) as well
as humans (Weindruch & Walford, 1988; Masoro, 2005; Fontana &
Klein, 2007). One of the main differences is that, unlike in elderly and
frail animals and humans (Fontana et al., 2013), inflammation is
extremely low in lean DR rodents and humans (Weindruch & Walford,
1988; Fontana & Klein, 2007; Meyer et al., 2006; Fontana et al., 2004),
and the partial inhibition of these anabolic and mitogenic pathways
(which when stimulated promote cancer and senescence) is driven by a
reallocation of metabolic resources from growth to somatic maintenance
and stress resistance (Fontana et al., 2010).
Unfortunately, only a small fraction of the US population (~7%) is
both normal weight and practicing a healthy lifestyle (i.e., not smoking,
exercising regularly, and eating a healthy diet) (Stampfer et al., 2000).
Therefore, the increasingly U-shaped relationship between BMI and
mortality with advancing age is probably the result of a diet-induced
overstimulation of several mitogenic and inflammatory pathways starting
early in life, which accelerates the accumulation of unrepaired cellular
damage and senescent cells, activates the DNA damage response,
inhibits the function of tissue stem cells, and promotes involuntary
weight loss, organ dysfunction, and frailty (Bartke et al., 2002; Herbig
et al., 2006; Schumacher et al., 2008; Fontana et al., 2010; Conboy &
Rando, 2012; Campisi, 2013; Lopez-Otın et al., 2013).
Clinical and public health implications
The long-standing controversy regarding the relationship between BMI
and mortality was heightened by a recent meta-analysis by Flegal et al.
(Flegal et al., 2013). However, this study was fraught with methodo-
logical problems, which led to misleading conclusion that being
overweight reduced mortality. A large body of epidemiological, clinical,
and basic science evidence indicates that lean people who maintain a
healthy body weight through a healthy diet and being physically active
have healthier metabolic profiles, a lower risk of developing chronic
disease, and a lower risk of mortality. In contrast, sedentary individuals
eating a typical Western diet with a BMI < 25 who experience
unintentional weight loss due to occult or preexisting chronic diseases
or aging, coupled with increased levels of cortisol and inflammation, and
low serum IGF-1 and/or testosterone concentrations may have an
increased risk of debilitating chronic disease, frailty, and mortality.
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Undoubtedly, prevention strategies to maintain a healthy body weight
and an optimal metabolic profile must start early, because even one
major cardiovascular risk factor at 50 years of age considerably increases
the risk of developing CVD and substantially shortens lifespan (Lloyd-
Jones et al., 2006).
There is ample convincing evidence that overweight and obesity exert
adverse influences on health and life expectancy to justify public health
campaigns to prevent excessive weight gain and to promote the
maintenance of a healthy weight throughout the lifespan. These data
also justify the current BMI cutpoints for normal weight, overweight, and
obesity. These standards should be primarily based on data that examine
the relationships between BMI and chronic disease incidence rather than
mortality, because mortality studies are highly susceptible to the
aforementioned methodological problems. In addition to assessing
BMI, it is important to monitor weight change after age 20 and changes
in waist circumference, both of which are significant predictors of
morbidity and mortality independent of current BMI. BMI should serve as
a guidepost for health through life stages, and the prevention of weight
gain is more important than weight loss because once an individual
becomes obese, it is very difficult to achieve long-term weight loss and
maintenance. In clinical settings, one should be sensible in the
application of BMI cutpoints to individual patients, because not all
patients who are modestly overweight need to lose weight, such as
physically active athletes or body builders (Kalkhoff & Ferrou, 1971). In
addition to assessing body weight and waist circumference, a metabolic
and hormonal profiling is necessary to evaluate an individual’s overall risk
of chronic diseases, frailty, and mortality.
Recently, the metabolically healthy but obese phenotype (overweight
and obese adults who have no sign of metabolic disorders) has received
much attention (Pataky et al., 2010; Stefan et al., 2013). However, this
state is likely to be transitory for most individuals, especially for those
who are not following a healthy diet nor exercising regularly (Appleton
et al., 2013). On the other end of the spectrum, many individuals are
normal weight but have an increased risk of metabolic diseases due to
increased visceral adiposity. This ‘normal-weight metabolically obese’
phenotype, which is particularly common in Asian populations, deserves
more clinical and public health attention (Chan et al., 2009). More
studies are needed to identify more precisely the optimal body weight
and metabolic/hormonal profile associated with successful aging and
healthy longevity, which may vary based on age, sex, and genetic
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Fig. 5 Dietary restriction (DR)-induced metabolic, molecular, and cellular adaptations. A chronic negative energy balance induced by dietary restriction triggers multiple
metabolic adaptations including a reduction in circulating levels of growth factors (i.e., IGF-1), anabolic hormones (e.g., insulin, testosterone, estradiol, leptin), inflammatory
cytokines (e.g., IL-6 and TNF-alpha), and key hormones that regulate thermogenesis and cellular metabolism (e.g., triiodothyronine (T3), cathecolamines), and an increase in
hormones that suppress inflammation (e.g., cortisol, ghrelin, and adiponectin). Concomitantly, several key molecular adaptations take place, including a down-regulation of
the insulin/IGF pathway (i.e., PI3K/Akt/mTOR), and an upregulation of two energy-sensing pathways (i.e., SIRT and AMPK) which activates FOXO. The activation of FOXO in
turn modifies several ‘longevity genes,’ including up-regulation of antioxidant genes (e.g., SOD2), DNA repair genes (e.g., DDB1), autophagy genes (e.g., beclin), and a
down-regulation of genes that control cell proliferation (e.g., cyclin D). DR induces also a down-regulation of inflammatory pathways (e.g., NFkB), and an up-regulation of
genes that enhance protection against molecular damage (e.g., Nrf2, HSP70). These DR-induced metabolic and molecular modifications are responsible for several important
cellular adaptations, that antagonize the accumulation of macromolecular damage, abnormal cell proliferation, and cellular senescence (Martin et al., 2006; Fontana et al.,
2007a,b; Fontana et al., 2010; Guarente, 2013; Selman & Withers, 2011; Chen et al., 2010).
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should derive from cohort studies with large sample sizes and long
follow-up periods from midlife or earlier.
Conclusions
The continuing controversy regarding overweight and mortality has
caused a great deal of confusion not only among the general public but
also among health professionals. This controversy underscores the many
methodological challenges in analyses of the relationship between BMI
and mortality, including reverse causation, confounding by smoking,
effect modification by age, and imperfect measures of adiposity.
However, evidence for the adverse impact of overweight and moderate
obesity on chronic disease incidence is overwhelming and indisputable.
In addition, mounting evidence indicates that being overweight
significantly reduces the probability of healthy aging. Many well-
conducted studies in large cohorts have shown that being overweight
does increase the risk of premature mortality. In these studies, after
accounting for residual confounding by smoking and reverse causation,
the lowest mortality is associated with a BMI < 25 kg m2. The optimal
BMI for most healthy middle-aged nonsmokers is likely to be in the
lower and middle part of the normal range. The range of BMI (<25) that
has been generally associated with desirable metabolic health and
successful aging is supported by abundant data from DR studies in
animal models and humans regarding metabolic parameters, disease
risk, and longevity.
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